Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression

Binabaj, Maryam Moradi, Soleimani, Atena, Rahmani, Farzad, Avan, Amir, Khazaei, Majid, Fiuji, Hamid, Soleimanpour, Saman, Ryzhikov, Mikhail, Ferns, Gordon A, Bahrami, Afsane and Hassanian, Seyed Mahdi (2019) Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression. Gene, 706. pp. 131-139. ISSN 0378-1119

[img] PDF - Accepted Version
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (320kB)

Abstract

The high mobility group A2 (HMGA2; also called HMGI-C) gene is an architectural transcription factor that belonging to the high mobility group AT-hook (HMGA) gene family. HMGA2 is aberrantly regulated in several human tumors. Over-expression of HMGA2 is correlated with a higher risk of metastasis and an unfavorable prognosis in patients with cancer. We performed a meta-analysis to determine the clinic-pathological and prognostic value of HMGA2 overexpression in different human tumors. A comprehensive literature search was performed using PubMed, Embase, Cochrane Library, Scopus, MEDLINE, Google Scholar and ISI Web of Science. Hazard ratios (HRs)/odds ratios (ORs) and their 95% confidence intervals (CIs) were used to assess the strength of the association between HMGA2 expression and overall survival (OS)/progression free survival (PFS)/disease free survival (DFS). A total of 5319 patients with 19 different types of cancer from 35 articles were evaluated. Pooled data analysis indicated that increased HMGA2 expression in cancer patients predicted a poor OS (HR = 1.70; 95% CI = 1.6–1.81; P < 0.001; fixed-effect model). In subgroup analyses, high HMGA2 expression was particularly associated with poor OS in individuals with gastrointestinal (GI) cancer (HR = 1.89, 95% CI: 1.83–1.96; fixed-effect model) and HNSCC cancer (HR-1.78, 95%CI: 1.44–2.21; fixed-effect model). Over-expression of HMGA2 was associated with vascular invasion (OR = 0.16, 95% CI = 0.05–0.49; P = 0.001) and lymphatic invasion (OR = 1.89, 95% CI = 1.06–3.38; P = 0.032). Further studies should be conducted to validate the prognostic value of HMGA2 for patients with GI cancers.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
Brighton and Sussex Medical School > Division of Medical Education
Subjects: R Medicine
Depositing User: Cherie Elody
Date Deposited: 17 Jun 2019 12:02
Last Modified: 02 May 2020 01:00
URI: http://sro.sussex.ac.uk/id/eprint/84330

View download statistics for this item

📧 Request an update